Health insurers have criticised the rising marketing budgets of pharmaceutical companies as the cost of medicaments in Switzerland spirals ever upwards. Santésuisse, the umbrella organisation for Swiss health insurers, has repeated calls to bring healthcare costs under control.
This content was published on
2 minutes
swissinfo.ch/mga
The SonntagsZeitungExternal link newspaper says that the marketing budget of Swiss pharma giant Novartis has risen 20% in the last four years to CH12 billion ($12 billion), eclipsing the CHF9 billion spent on research. Roche has increased marketing costs by 15% in the same period.
“The marketing and distribution costs of the pharmaceutical industry are disproportionately high,” complains Guido Klaus of the health insurer Helsana. But the pharma companies argue that they must spend money informing doctors of their new innovations. Studies show marketing costs at international rivals also increasing.
The rising cost of healthcare, and the resulting pressure on health insurance premiums, has been a major talking point in Switzerland for several years. In June, Santésuisse warned that health insurance premiums would likely rise 3% both this year and next.
SonntagsZeitung says the cost of cancer treatments to health insurers has risen from CHF580 million in 2013 to CHF940 million and is set to break the CHF1 billion barrier in 2019. The cost of treating patients in their homes will also reach CHF1 billion soon, Santésuisse warns.
To counter rising costs, more health insurers are taking advantage of laws introduced at the start of this year that allow pharmacists to supply certain prescription medicines without consulting a doctor, reports the Le Matin DimancheExternal link newspaper.
The Groupe Mutuel insurer in the French-speaking part of Switzerland, is ramping up cooperation with pharmacies as a result. There are at least three other insurers that have adopted similar models, says the newspaper.
Popular Stories
More
Banking & Fintech
UBS releases ‘hundreds’ of staff in fresh wave of job cuts
Should Switzerland take measures to support its struggling industries?
Industrial policies are back in fashion, not only in the United States but also in the EU. Should Switzerland, where various industries are struggling, draw inspiration from such policies?
As a Swiss Abroad, how do you feel about the emergence of more conservative family policies in some US states?
In recent years several US states have adopted more conservative policies on family issues, abortion and education. As a Swiss citizen living there, how do you view this development?
This content was published on
The parents of the young jihadist who left for Syria to join the Islamic State have been given suspended sentences by the Federal Criminal Court.
This content was published on
Felix Lehner, Pamela Rosenkranz and Miroslav Sik have been awarded the Swiss Grand Award for Art/Prix Meret Oppenheim 2025.
Nearly 2% of new Swiss disability insurance claims involve Long Covid
This content was published on
Just under 2% of new claims submitted to the disability insurance between 2021 and 2023 concern people suffering from Long Covid.
This content was published on
The watch industry had to contend with a weakening of its exports last year, which reached a volume of CHF25.9 billion ($28.5 billion).
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Swiss healthcare costs expected to rise well above inflation
This content was published on
On Monday, SantésuisseExternal link outlined the main reasons for the expected increases in health insurance policies. It predicts a 6% rise in physiotherapy treatments, the same greater demand for care for the elderly and in nursing homes and 5% extra medical diagnostics being performed in laboratories. In addition, insurers expect costs to rise to a…
US Senate asks Novartis to shed light on data manipulation allegations
This content was published on
The Swiss pharmaceutical firm Novartis has been asked to provide details regarding possible data inaccuracies for its human gene therapy Zolgensma.
This content was published on
Curing cancer for the masses could be challenging if healthcare systems are crippled by rapidly rising cancer drug prices.
Generic drugs remain twice as expensive in Switzerland
This content was published on
Drug prices in Switzerland remain higher than in other major European markets, especially when it comes to generic drugs, which are twice as expensive in Switzerland as elsewhere.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.